Q3 Financial Results Presentation for Fiscal Year Ending March 2026

Performance Overview

For the third quarter of the fiscal year ending March 2026, revenue increased 9.0% YoY to 216,025 million yen, and net income attributable to owners of parent rose 32.6% to 4,671 million yen, a record high since the company's founding. Operating and ordinary income decreased YoY, influenced by changes in expense recognition methods within the pharmaceutical segment. By segment, the pharmacy business saw increased technical fee unit prices due to promotion of medical DX and a higher usage ratio of generic drugs, while the number of receptions declined, resulting in higher revenue but lower profit. The BPO business achieved higher revenue and profit due to increased demand for dispatched Medical Representatives. Despite significant contributions from new products, the pharmaceutical business's operating income declined due to changes in expense recognition.

Plan Progress and Future Outlook

Progress against full-year plan stands at 77.2% for revenue, 60.7% for operating income, 60.8% for ordinary income, and 66.7% for net income attributable to owners of parent. The store strategy includes reviewing the portfolio according to regional characteristics and expanding scale through M&A and new store openings, strategically focusing on the Tokyo, Nagoya, and Osaka areas. As revisions to dispensing fees and healthcare system reforms impact quarterly technical fee trends, ongoing monitoring is required.